Human Health Division (HHD) Products

Veterinary Division (VET)
Product List by Therapeutic
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Mometasone Furoate

Composition
Momespray: Each spray delivers Mometasone Furoate BP 50 mcg.
Pharmacology
Momespray is a corticosteroid demonstrating
anti-inflammatory properties. The precise mechanism of
corticosteroid action on allergic rhinitis is not known.
Corticosteroids have been shown to have a wide range of
effects on multiple cell types (e.g, mast cells, eosinophils,
neutrophils, macrophages, and lymphocytes) and
mediators (e.g, histamines, eicosanoids, leukotrienes,
and cytokines) involved in inflammation. Protein binding
for Mometasone Furoate was reported to be 98% to 99%
in concentration range of 5 to 500 ng/ml.The effective
plasma elimination half-life of Mometasone Furoate is 5.8
hours.
Indication
Momespray is indicated for the treatment of the nasal
symptoms of seasonal and perennial allergic rhinitis, in
adults and pediatric patients 2 years of age and older. It
is indicated for the prophylaxis of the nasal symptoms of
seasonal allergic rhinitis in adult and adolescent patients
12 years and older. It is also indicated for the treatment of
nasal polyps in patients 18 years and older.
Dosage & Administration
Administer Mometasone Nasal Spray by the intranasal
route only.
Allergic Rhinitis
Adults and Children 12 Years of Age and Older: For
prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal symptoms of perennial allergic rhinitis use two sprays (50 mcg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 mcg). In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis use
Momespray 50 mcg (200 mcg/day) 2 to 4 weeks prior to the anticipated start of the pollen season.
Children (2 to 11 years of age)
For treatment of the nasal symptoms of seasonal and perennial allergic rhinitis use one spray (50 mcg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 mcg).
Nasal Polyps
Adults 18 years of Age and Older: For nasal polyps use two sprays (50 mcg of Mometasone Furoate in each spray) in each nostril twice daily (total daily dose of 400 mcg). A dose of two sprays (50 mcg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 mcg) is also effective in some patients or as directed by the physician.

Download Label

Lornoxicam

Composition

Loxodol 4 : Each film coated tablet contains Lornoxicam INN 4 mg. Loxodol 8 : Each film-coated tablet contains Lornoxicam INN 8 mg.

Pharmacology

Lornoxicam belongs to oxicam group and non-steroidal anti-inflammatory drug (NSAID), with analgesic, anti-pyretic, anti-thrombotic and anti-inflammatory activities. Upon oral administration, lornoxicam binds to and inhibits the activity of the cyclooxygenase enzymes (COX) type 1 (COX-1) and type 2 (COX-2) by the ratio of 1:1. It readily penetrates into the synovial fluid. This leads to reduced prostaglandin and thromboxane production and decreased pain, fever and inflammation. Lornoxicam is well absorbed orally and has half-life of around 3-4 hours. The onset of action can be observed within 30 to 60 minutes of administration and eliminated via liver and kidneys ( 42%).

Indications

Indicated for the treatment of mild to moderate pain in osteoarthritis, surgery, sciatica and other inflammations.

Dosage & Administration

For Pain relief: In Adult: 8-16 mg daily in 2-3 divided doses. Max: 16 mg daily. In Osteoarthritis & Rheumatoid arthritis: Adult: 12 mg daily in 2-3 divided doses, up to 16 mg daily if needed. For patients with renal/liver impairment: Maximum 12 mg daily in 2-3 divided doses. It should be taken 1 hour before meal or 2 hours after meal to minimize gastrointestinal irritation or as directed by the physician.

Contraindications

Contraindicated in patients with peptic ulcer, severe kidney impairment and hypersensitivity. Lornoxicam can increase risk of fatal heart attack or stroke.

Warnings & Precautions

It is not recommended to administer Lornoxicam to patients with history of peptic ulcer, hypersensitivity, impaired kidney or liver function, high blood pressure, heart failure, ulcerative colitis or Crohn's disease, asthma and lupus erythematosus, diabetes or blood coagulation disorder.

Side Effects

The most common side effects are: Gastrointestinal: Abdominal pain, diarrhea, indigestion, nausea, vomiting, inflammation of pancreas and mouth ulcer. Central Nervous System: Headache, drowsiness, sleeplessness and dizziness. Eye and ENT: Visual disturbance, ringing in ear and sensitivity to light. Heart: High blood pressure, palpitations and fluid retention. Skin: Skin rash.

Use in Pregnancy & Lactation

Lornoxicam is not recommended during pregnancy and breastfeeding and is contraindicated during the last third of pregnancy.

Use in Children & Adolescents

Due to lack of data, Lornoxicam is not indicated for children and adolescents below 18 years old.

Drug Interactions

Combination with Vitamin K antagonists like warfarin increases the risk of bleeding. Combination with Cyclosporin can lead to reduced kidney function, and to acute kidney injury in rare cases. Lornoxicam can also increase the adverse effects of lithium, methotrexate and digoxin and its derivatives. The effect of diuretics, ACE inhibitors and angiotensin II receptor antagonists can be reduced, in patients with heart failure.

Overdosage

Symptoms: Increased side effects from the central nervous system and gastrointestinal tract, increased blood pressure, cardiac and / or acute renal failure. Treatment: Gastric lavage, appointment of activated carbon & monitoring of vital functions.

Storage

Store below 30°C, away from light and in a dry place. Keep all medicines out of the reach of children. Packing:

Loxodol 4 : Each box contains 3 X 10 tablets in Alu-Alu blister & an insert. Loxodol 8 : Each box contains 3 X 10 tablets in Alu-Alu blister & an insert.

Download Label

Ketorolac

Composition:
OrcTM Tablet: Each film coated tablet contains Ketorolac Tromethamine USP 10 mg.
OrcTM 30 IV/IM injection: Each 1 ml ampoule contains Ketorolac Tromethamine USP 30 mg.
OrcTM 60 IV/IM injection: Each 2 ml ampoule contains Ketorolac Tromethamine USP 60 mg.

Indication:
OrcTM tablets are indicated for short term management of moderate postoperative pain and acute & chronic musculoskeletal pain as a continuation of treatment.
OrcTM injections are indicated for short term management of moderate to serve acute post-operative pain.

Dose & Administration:
OrcTM tablets: Ketorolac Tromethamine 10 mg tablet 4-6 hourly; Elderly 6-8 hourly. Maximum dose is 40 mg daily.
OrcTM Injection: Adult patient (<65 years): Ketorolac Tromethamine is for administration by intramuscular or intravenous injection. Initial dose is 60 mg IM or 30 mg IV. Maintenance dose is 30 mg IM/IV 6 hourly.

Download Label

Momeasone

Composition:

Momespray™: Each spray contains Mometasone Furoate BP 50 meg.


Indication:

Momespray™ is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older. It

is indicated for the prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older. It is also indicated for the treatment of

nasal polyps in patients 18 years and older.


Dose & Administration:

Administer Mometasone Nasal Spray by the intranasal route only.

Allergic Rhinitis

Adults and Children 12 Years of Age and Older: For prophylaxis and treatment of the nasal symptoms of seasonal allergic rhinitis and treatment of the nasal

symptoms of perennial allergic rhinitis use two sprays (50 meg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 meg). In patients

with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis use Momespray™ 50 meg (200 meg/day) 2 to 4 weeks prior

to the anticipated start of the pollen season.


Children (2 to 11 years of age) For treatment of the nasal symptoms of seasonal and perennial allergic rhinitis use one spray (50 meg of Mometasone Furoate in each spray) in each nostril once daily (total daily dose of 100 meg).

Nasal Polyps

Adults 18 years of Age and Older: For nasal polyps use two sprays (50 meg of Mometasone Furoate in each spray) in each nostril twice daily (total daily dose of 400

meg). A dose of two sprays (50 meg of mometasone furoate in each spray) in each nostril once daily (total daily dose of 200 meg) is also effective in some patients.


Download Label

Fluticasone Propionate + Azelastine

Composition:
Flutispray™ Plus: Each spray delivers Fluticasone Propionate BP 50 meg and Azelastine hydrochloride BP 137 meg.

Indication:
Flutispray™ Plus is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 6 years of age and older who require treatment with both Azelastine Hydrochloride and Fluticasone Propionate for symptomatic relief.

Dose and Administration:
The recommended dosage of Flutispray™ Plus is one spray in each nostril twice daily.

Download Label